Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Mar;79(3):370-8.
doi: 10.1111/bcp.12467.

Clinical trials of medicines in neonates: the influence of ethical and practical issues on design and conduct

Mark A Turner  1
Affiliations
Review

Clinical trials of medicines in neonates: the influence of ethical and practical issues on design and conduct

Mark A Turner. Br J Clin Pharmacol. 2015 Mar.

Abstract

In the past, there has been a perception that ethical and practical problems limit the opportunities for research in neonates. This perception is no longer appropriate. It is now clear that research about the medicines used in neonates is an ethical requirement. It is possible to conduct high quality research in neonates if the research team adapt to the characteristics of this population. Good practice involves respecting the specific needs of newborn babies and their families by adopting relevant approaches to study design, recruitment, pharmacokinetic studies and safety assessment. Neonatal units have a unique culture that requires careful development in a research setting. Clinical investigators need to recognize the clinical and ethical imperative to conduct rigorous research. Industry needs to engage with neonatal networks early in the process of drug development, preferably before contacting regulatory agencies. Follow-up over 3-5 years is essential for the evaluation of medicines in neonates and explicit funding for this is required for the assessment of the benefit and risk of treatments given to sick newborn babies. The views of parents must be central to the development of studies and the research agenda. Ethical and practical problems are no longer barriers to research in neonates. The current challenges are to disseminate good practice and maximize capacity in order to meet the need for research among newborn babies.

Keywords: clinical trials; ethics; neonate; patient and public involvment; pharmacokinetics; regulatory affairs.

PubMed Disclaimer

References

    1. Giacoia GP, Taylor-Zapata P, Zajicek A. Drug studies in newborns: a therapeutic imperative. Clin Perinatol. 2012;39:11–23. - PubMed
    1. Baer GR. Ethical issues in neonatal drug development. In: Mulberg AE, Silber SA, Van den Anker JN, editors. Pediatric Drug Development: Concepts and Applications. Hoboken, NJ, USA: John Wiley and Sons; 2009. pp. 103–13.
    1. EMA. 2013. European Network of Paediatric Research at the European Medicines Agency (ENPR-EMA). Available at http://www.ema.europa.eu/ema/index.jsp?curl=pages/partners_and_networks/... (last accessed 3 August 2014)
    1. GRiP. 2013. Report on existing neonatal networks outside EU. Available at http://www.grip-network.org/index.php/cms/en/drug_development_neonates (last accessed 3 August 2013)
    1. PTN. 2013. Pediatric trials network. Available at https://pediatrictrials.org/ (last accessed 3 August 2014)

Publication types

MeSH terms

Substances